Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Loading ETF research
Fetching the latest fund profile, holdings, and market data.
New York Stock Exchange ArcaEquity
Previous close
$26.975
−$0.2152 · -0.79%
Sep 4, 3:59 PM ET
Regular session · ET · Market data may be delayed.
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Fund assets
5.39M USD
Expense ratio
0.59%
NAV
$26.93
Average volume
1.95K
Volume
285
Day range
$26.945 – $27.055
52-week range
$22.629 – $27.94
Previous close
$27.1902
Price change
1 day
-0.79%
1 month
+3.75%
3 months
+10.96%
Year to date
+6.96%
1 year
+15.43%
3 years
+6.20%
5 years
+6.20%
Price changes exclude distributions, fees, taxes, and investor-specific cash flows.
Portfolio
Holdings data updated Sep 6, 2026.
Portfolio composition
Fund income
Dec 30, 2025
Dec 30, 2025
Dec 31, 2025
$0.4132
Irregular
Dec 30, 2024
Dec 30, 2024
Dec 31, 2024
$0.2199
Annual
Latest coverage
More funds
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.
